Steroid Response in Refractory Asthmatics

An-Soo Jang

Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

Inhaled glucocorticosteroids are currently the most effective anti-inflammatory controller medications for treating persistent asthma. The efficacies of glucocorticoids include reducing asthma symptoms, reducing exacerbation frequency, improving quality of life, improving lung function, decreasing airway hyperresponsiveness, controlling airway inflammation, and reducing mortality. However, the treatment response to glucocorticosteroids in asthmatics varies, and certain subtypes of asthma, such as refractory asthma, respond poorly to high-dose inhaled glucocorticoid and systemic steroids. The medical costs of treating refractory asthmatics represent about 50% of the total healthcare cost for asthma. A thorough understanding of the mechanisms of glucocorticoid action, patient responses to glucocorticoids, and steroid resistance observed in refractory asthmatics is necessary for the targeted development of therapeutic drugs. This review discusses the characteristics of severe refractory asthmatics and the mechanisms of steroid response and resistance in asthma treatment.

Keywords: Glucocorticoids; Drug resistance; Asthma

INTRODUCTION

Asthma is a chronic inflammatory airway disease involving episodic breathlessness and wheezing with airway hyperresponsiveness to environmental stimuli [1-3]. Airway inflammation in asthmatic patients is characterized by degranulated mast cells, infiltrating eosinophils, and an increased number of activated helper T-lymphocytes [1-3]. In asthma, many different inflammatory mediators such as lipid mediators, inflammatory peptides, chemokines, cytokines, and growth factors are increased [1-3]. The structural cells of the airways, including epithelial cells, airway smooth muscle cells, endothelial cells, and fibroblasts, also are a major source of inflammatory mediators in asthma [3]. Airway remodeling in both large and small airways has been documented in all degrees of asthma severity [4]. Structural changes in airway remodeling include loss of epithelial integrity, thickening of the basement membrane, subepithelial fibrosis, goblet cell and submucosal gland enlargement, increased smooth muscle mass, decreased cartilage integrity, and increased airway vascularity [4-7]. Inhaled glucocorticoids are currently the most effective anti-inflammatory controller medications for the treatment of persistent asthma [1-3] in Korea [1,2] and are recommended by the Global Initiative for Asthma (GINA) guidelines [3].

The prevalence of asthma is about 5-10% of the general population. Of these, approximately 5-10% are severe refractory asthmatics who respond poorly to asthmatic drugs, including high-dose inhaled steroids [5-12]. Severe refractory asthmatics have persistent symptoms, frequent symptom exacerbation, and severe airway obstruction even when taking high-dose inhaled steroids.
The subtypes of severe asthma [13-18] include fatal or near fatal asthma, steroid-dependent asthma, steroid-resistant asthma, difficult-to-control asthma, poorly controlled asthma, brittle asthma, and irreversible asthma. Patients who do not reach an acceptable level of control at step 4 of the GINA guidelines (reliever medication plus two or more controllers) are defined as having difficult-to-control asthma [3]. The American Thoracic Society [16] has defined refractory asthma (RA) as followings. RA was defined by one or both major criteria and one minor criteria as followings: 1) major criteria: treatment with continuous or near continuous (> 50% of year) oral corticosteroids (CS), requirement for treatment with high-dose inhaled CS; 2) minor criteria: a) requirement for daily treatment with a controller medication in addition to inhaled CS, e.g., long-acting β-agonist, theophylline, or leukotriene antagonist, b) asthma symptoms requiring short-acting β-agonist use on a daily or near daily basis, c) persistent airway obstruction (forced expiratory volume in one second [FEV1] < 80% predicted, diurnal peak expiratory flow [PEF] variability > 20%), d) one or more urgent care visits for asthma per year, e) three or more oral steroid “bursts” per year, f) prompt deterioration with ≤ 25% reduction in oral or inhaled corticosteroid dose, g) near fatal asthma event in the past.

This review discusses the characteristics of severe asthma, including RA, and the mechanisms of steroid response and steroid resistance in the treatment of asthma.

**Table 1. Subtypes of difficult to control asthma**

| Subtype of Asthma                        |
|-----------------------------------------|
| Steroid-resistant asthma                |
| Steroid-dependent asthma                |
| Brittle asthma                          |
| Asthma with fixed obstruction           |
| Adult-onset asthma                      |
| Nocturnal asthma                        |
| Aspirin-induced asthma                  |
| Premenstrual asthma                     |
| Acute, severe asthma                    |
| Status asthmatic                        |
| Fatal asthma                            |

**CHARACTERISTIC OF SEVERE ASTHMA**

**Subtypes of difficult-to-control asthma (Table 1)**

Brittle asthma is diagnosed in patients with severe and unstable asthma who maintain a wide variability of PEF despite high doses of inhaled steroids. Type 1 brittle asthma is characterized by a wide, persistent, and chaotic PEF variability (> 40% diurnal variation for > 50% of the time over a period of at least 150 days) despite considerable medical therapy. Type 2 brittle asthma involves sudden acute attacks without an obvious trigger and lasting less than 3 hours in patients with apparently normal airway function or well-controlled asthma.

Nocturnal asthma has an early morning dip and double dip. Premenstrual asthma is unstable asthma that occurs 2-5 days before menses. Steroid-resistant asthma is diagnosed in those rare patients who take high-dose steroids (10- to 14-day course of prednisone ≥ 20 mg twice daily), but experience less than 15% improvement from baseline FEV1. Steroid-dependent asthma is defined as asthma that can be controlled only with high-dose steroids; it may be part of a continuum with steroid-resistant asthma at the other extreme.

Acute and severe asthma are diagnosed in patients with acute or subacute exacerbation with dyspnea, wheezing, chest tightness, and decreased lung function. Status asthmaticus leads to acute respiratory failure and can cause death (fatal asthma). Severe asthma is classified according to cell type, e.g., eosinophils and neutrophils [18-21]. Eosinophilic asthma observed on bronchoalveolar lavage and mucosal biopsy causes decreased lung function and occasional near-fatal events.

**Clinical characteristics of severe asthma**

Severe asthma, including RA, represents 10-20% of asthma cases and is associated with more drug medications and more hospital visits and admissions than mild to moderate asthma. Mortality occurs in 3-35% of severe asthma cases, and the medical cost to treat severe asthma is more than 50% of the total medical cost for treating asthmatic patients [22].

Risk factors for severe asthma are genetic and environmental, including many kinds of aeroallergens, beta-blockers, and anti-inflammatory drugs. Gastroesophageal reflux disease can affect asthma symptoms.
through esophagopharyngeal reflux and aspiration. In addition, factors such as denial, anxiety, fear, depression, socioeconomic status, and alcohol consumption can exacerbate asthma. Differential diagnoses [17] include smoking, chronic obstructive pulmonary disease, bronchiectasis, allergic bronchopulmonary aspergillosis, chronic infection, rhinosinusitis, vocal cord dysfunction, thyroid diseases, and inappropriate drug use. Among the genetic factors reported to be related to severe asthma are genetic variants of interleukin (IL)-4, IL-4 receptor, IL-9, IL-10, IL-1α, glutathione S-transferase, β2 receptor homozygous Gly-16 polymorphism, transforming growth factor (TGF)-β1, monocyte chemotactic protein, leukotriene C4 synthase, and 5-lipoxygenase [23-26].

**Pathophysiological characteristics of severe asthma**

Severe asthma can be classified based on four different pathological aspects.

1) Persistent airway inflammation despite maximal medication occurs in one-half to two-thirds of patients with severe asthma. In these patients, an increase in T-lymphocyte activating mediator is seen on mucosal biopsy; increases in the innate response factor tryptase, TGF-β2, cysteinyl leukotrienes, and 15-hydroxyeicosatetraenoic acid are found in the bronchoalveolar lavage fluid; and a thickening of the subepithelial basement membrane is observed [27]. 2) Severe asthma can be categorized based on the number of neutrophils or eosinophils [28]. An increase in the number of neutrophils can result in bronchiolitis obliterans, and a decrease in the number of eosinophils can be caused by steroid treatment [19-21]. 3) Severe asthma is associated with high-grade airway remodeling characterized by basement membrane thickening, epithelial denuding, airway smooth muscle thickening, and angiogenesis [4-6]. Submucosal fibroblasts secrete TGF-β, etoxin, IL-4, and IL-13, causing collagen deposition and basement thickening. Activated macrophages secrete immunoglobulin, collagen I, collagen III, tenasin, and fibronectin, leading to reticular basement thickening and subepithelial fibrosis [29]. Reticular basement thickening is related to asthma severity [30,31]. 4) Severe asthma can also be classified according to changes in both large and small airways [32].

**MECHANISMS OF STEROID**

**Steroid responses**

Glucocorticoids, the mainstay of asthma management, bind to glucocorticoid receptors (GRs) in the cytosol, thereby activating the translocation of GRs to the nucleus. In the nucleus, GR binds to specific gene regulatory elements to induce the expression of genes involved in regulating airway inflammation (Table 2) [33].

In a study of steroid responses in patients with moderate to severe asthma, the relationship between responsiveness and the FEV1% predicted and blood and sputum eosinophil levels prior to glucocorticoid inhalation was assessed.

**Table 2. Effect of corticosteroids on gene transcription**

| Increased transcription | Decreased transcription |
|-------------------------|------------------------|
| Annexin-1 (lipocortin-1, phospholipase A2 inhibitor) | Cytokines |
| β2-adrenoceptors | IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-11, IL-12, IL-13, IL-16, IL-17, IL-18, TNFα, GM-CSF, stem cell factor |
| Clara cell protein (CC10, phospholipase A2 inhibitor) | Chemokines |
| Glucocorticoid-induced leucine zipper protein | IL-8, RANTES, MIP-1α, MCP-1, MCP-3, MCP-4, eotaxins |
| Interleukin (IL)-1 receptor antagonist | Adhesion molecules |
| Inhibitor of NF-κB (IκB-α) | E-selectin, ICAM-1, VCAM-1 |
| IL-10 | Inflammatory enzymes |
| Mitogen-activated protein kinase phosphatase-1 | Cytoplasmic phospholipase A2 |
| Secretory leukoprotease inhibitor | Inducible cyclooxygenase (COX-2) |
| Decreased transcription | Inducible nitric oxide synthase |
| Chemokines | Inflammatory receptors |
| E-selectin, ICAM-1, VCAM-1 | Bradykinin B2-receptors |
| TNFα, GM-CSF, stem cell factor | Tachykinin NK1-receptors, NK2-receptors |
| Adhesion molecules | Peptides |
| IL-8, RANTES, MIP-1α, MCP-1, MCP-3, MCP-4, eotaxins | Endothelin-1 |

Reprinted from Barnes [33] with permission from Elsevier.

TNF, tumour necrosis factor; GM-CSF, granulocyte–macrophage colony stimulating factor; RANTES, released by normal activated T cells expressed and secreted; MIP, macrophage inflammatory protein; MCP, monocyte chemoattractant protein; ICAM, intercellular adhesion molecule; VCAM, vascular–endothelial cell adhesion molecule.
tion were investigated [28]. In this study, 86 adult asthmatic outpatients with an initial FEV1 < 80% received a glucocorticoid inhalant (fluticasone propionate 1,000 μg/day) for 4 weeks. The percentage change in FEV1 after treatment was determined as [(FEV1_{4 weeks} - FEV1_{baseline}) / FEV1_{baseline}] × 100. The asthmatic patients showing a change of > 12% in FEV1 (n = 46, 53.4%) after treatment had a significantly higher proportion of blood eosinophils and a lower FEV1 volume (in liters) prior to treatment. The percentage change in FEV1 correlated with the number of sputum eosinophils prior to glucocorticoid inhalation ($r = 0.242; p < 0.05$) and correlated inversely with the FEV1% predicted prior to glucocorticoid inhalation ($r = -0.462; p < 0.001$). Thus, the FEV1% predicted and blood and sputum eosinophil levels prior to glucocorticoid inhalation were associated with the responsiveness to inhaled glucocorticoids in patients with moderate to severe asthma.

There was a wide range of steroid responsiveness in asthmatics with moderate to severe asthma in the above study [28] (FEV1, -21 to 126.8%; forced vital capacity, -20 to 47%; forced expiratory flow, -55.1 to 95%) (Fig. 1). This emphasizes the importance of investigating the mechanisms responsible for steroid unresponsiveness in asthma treatment. Korean and GINA guidelines [1-3] recommend a treatment strategy according to asthma control status, but the guidelines do not address the non-responder group. Potential new drugs are necessary to reverse steroid unresponsiveness in controlling asthma symptoms in refractory asthmatics.

The following factors must be considered when using high-dose inhaled steroids or systemic steroids to treat RA: 1) method of drug delivery, e.g., steroid inhaler; 2) presence of environmental factors that may aggravate asthma symptoms; 3) possibility of co-morbid diseases such as vocal cord dysfunction, gastroesophageal reflux disease, and chronic sinusitis; 4) psychological factors and patient compliance in taking asthmatic drugs; 5) presence of infections (Chlamydia Mycoplasma); 6) possible failure in activation or rapid clearance of prednisolone; and 7) simultaneous administration of other medications such as rifampin, phenytoin, carbamazepin, phenobarbital, and anticonvulsants.

Steroid resistance
Those rare patients with steroid-resistant asthma exhibit less than 15% improvement in baseline FEV1 after a 10- to 14-day course of high-dose steroids (prednisone ≥ 20 mg twice daily). Proposed mechanisms leading to steroid resistance in asthma include intrinsic defects in neutrophils and mast cells, airway structural abnormalities, increases in inflammatory mediators related to steroid receptors, decreases in steroid receptor number and/or binding capacity, increases in GR-β, transcriptional factor repression, existence of steroid-resistant neutrophils, imbalance between acetylation and deacetylation, and airway remodeling [6,34,35].

Factors that may contribute to steroid resistance are listed in Table 3 [35,36]. These include a decreased number and/or genetic variation of GR; abnormal GR binding capacity; decreased DNA-binding activity of GR; alterations in transcription factors such as AP-1; immune dysregulation related to cytokines, chemokines, IL-4, p50 nuclear factor-κB, or signal transducer and activator of transcription-4; mitogen-activated protein kinase phosphatase-2 single nucleotide polymorphism; increased neutrophils; viral infections; allergens; mycobacterial infections; and smoking.

NEW THERAPEUTIC DRUG TRIALS IN RA
Currently, clinical trials are evaluating several drugs for the treatment of severe asthma and RA, including
methotrexate, gold, cyclosporine, intravenous gamma globulin, and macrolide antibiotics. However, the effects of these drugs on severe RA are minimal. In addition, phosphatidylinositol 3-kinase inhibitors, activated p38 MAP kinase inhibitors, and vitamin D3 to induce IL-10 production are undergoing therapeutic trials. Recent medical advances in the pathophysiological mechanism of asthma have led to the development of many asthma drugs [36-40]. New steroids, new bronchodilators, phosphodiesterase-4 inhibitors, transcription factor inhibitors, adhesion inhibitors, mediator antagonists, antioxidants, anti-IgE antibodies, cytokine inhibitors and antagonists, chemokine receptor inhibitors and agonists, and sublingual immunotherapy have been developed [41].

CONCLUSIONS

Glucocorticoids are mainstay therapeutic drugs for decreasing airway inflammation in asthma. Refractory asthmatics represent 5-10% of all asthmatics, but account for more than 50% of the total treatment cost of asthma. Understanding the pathophysiology of severe asthma, RA, and steroid-resistant asthma is necessary for the development of effective therapeutics. In order to develop individualized treatment approaches to severe RA, continued research is needed to identify genetic and environmental factors and to define the mechanisms of ongoing immune regulation and steroid responses.

Table 3. Proposed mechanisms of corticosteroid resistance in asthma

| Genetic abnormalities in glucocorticoid receptors (GRs) |
| Pharmacokinetic abnormalities (drug effects) |
| Lipocortin-1 antibodies |
| Effects of Th2 cytokines (interleukin [IL]-2 + IL-4, IL-13) |
| Increased GR-β |
| p38 MAP kinase activation |
| Reduced IL-10 secretion |
| Increased activation of AP-1 (activation of Jun-N terminal kinase) |
| Abnormalities in histone acetylation |
| Oxidative stress and cigarette smoking |
| Latent viral infections |

Reprinted from Barnes [36] with permission from the American Thoracic Society.

Conflict of interest
No potential conflict of interest relevant to this article was reported.

REFERENCES

1. The Korean Academy of Asthma, Allergy and Clinical Immunology. Treatment 2007 Korea adult asthma treatment guideline [Internet]. Seoul (KR): The Korean Academy of Asthma, Allergy and Clinical Immunology, c2005 [cited 2012 Mar 20]. Available from: http://www.allergy.or.kr.
2. The Korean Academy of Asthma, Allergy and Clinical Immunology. Treatment guideline of asthma in Korea [Internet]. Seoul (KR): The Korean Academy of Asthma, Allergy and Clinical Immunology, c2005 [cited 2012 Mar 20]. Available from: http://www.allergy.or.kr.
3. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma (EPR-3) [Internet]. Bethesda (MD): National Heart, Lung, and Blood Institute, 2007 [cited 2012 Mar 20]. Available from: http://www.nhlbi.nih.gov/guidelines/asthma.
4. James AL, Maxwell PS, Pearce-Pinto G, Elliot JG, Carroll NG. The relationship of reticular basement membrane thickness to airway wall remodeling in asthma. Am J Respir Crit Care Med 2002;166(12 Pt 1):1590-1595.
5. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997;111:852-857.
6. Reed CE. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 1999;103:539-547.
7. Ten Hacken NH, Postma DS, Timens W. Airway remodeling and long-term decline in lung function in asthma. Curr Opin Pulm Med 2003;9:9-14.
8. Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy 2003;33:1622-1628.
9. Wenzel S. Severe/fatal asthma. Chest 2003;123(3 Suppl):405S-410S.
10. Wenzel S. Severe asthma: epidemiology, pathophysiology and treatment. Mt Sinai J Med 2003;70:185-190.
11. Heaney LG, Robinson DS. Severe asthma treatment: need for characterizing patients. Lancet 2005;365:974-976.
12. Heaney LG, Conway E, Kelly C, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003;58:561-566.
13. Stirling RG, Chung KF. Severe asthma: definition and mechanisms. Allergy 2001;56:825-840.
14. Afzal M, Tharratt RS. Mechanical ventilation in severe asth-
148 The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012

ma. Clin Rev Allergy Immunol 2001;20:385-397.
15. Robinson DS, Campbell DA, Durham SR, et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003;22:478-483.
16. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions: American Thoracic Society. Am J Respir Crit Care Med 2000;162:2341-2351.
17. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J 1998;12:1209-1218.
18. Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999;13:1198-1208.
19. Chu HW, Trudeau JB, Balzar S, Wenzel SE. Peripheral blood and airway tissue expression of transforming growth factor beta by neutrophils in asthmatic subjects and normal control subjects. J Allergy Clin Immunol 2000;106:1115-1123.
20. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470-477.
21. Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma. Allergy 2003;50:23-29.
22. National Asthma Education and Prevention Program. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics-2002. J Allergy Clin Immunol 2002;110(5 Suppl):S141-S219.
23. Sandford AJ, Chugani T, Zhu S, et al. Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol 2000;106(1 Pt 1):135-140.
24. Spiteri MA, Bianco A, Strange RC, Fryer AA. Polymorphisms at the glutathione S-transferase, GSTP1 locus: a novel mechanism for susceptibility and development of atopic airway inflammation. Allergy 2000;55 Suppl 61:15-20.
25. Chu HW, Balzar S, Westcott JY, et al. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. Clin Exp Allergy 2002;32:1558-1565.
26. Szalai C, Kozma GT, Nagy A, et al. Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol 2001;108:375-381.
27. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-1008.
28. Jang AS, Lee JH, Park SW, et al. Factors influencing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma. Chest 2005;128:1140-1145.
29. Vignola AM, Mirabella F, Costanzo G, et al. Airway remodeling in asthma. Chest 2003;123(3 Suppl):417S-422S.
30. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989;140:1745-1753.
31. Takeyama K, Fahy JV, Nadel JA. Relationship of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med 2001;163:511-516.
32. Carroll NG, Mutavdzic S, James AL. Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002;19:879-885.
33. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006;533:2-14.
34. Leung DY, Hamid Q, Vottero A, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997;186:1567-1574.
35. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005;172:149-160.
36. Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004;1:264-268.
37. Chung KF. Individual cytokines contributing to asthma pathophysiology: valid targets for asthma therapy? Curr Opin Investig Drugs 2003;4:1320-1326.
38. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004;3:831-844.
39. Hedley ML. Gene therapy of chronic inflammatory disease. Adv Drug Deliv Rev 2000;44:195-207.
40. Bryan SA, Leckie MJ, Hansel TT, Barnes PJ. Novel therapy for asthma. Expert Opin Investig Drugs 2000;9:25-42.
41. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-1087.